KR
Therapeutic Areas
Monopar Therapeutics Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Validive (clonidine HCl MBT) | Prevention of severe oral mucositis in head and neck cancer patients receiving chemoradiotherapy | Phase 2b/3 |
| MNPR-101 | Advanced cancers (e.g., pancreatic, triple-negative breast cancer) | Preclinical |
| MNPR-202 (camsirubicin) | Advanced soft tissue sarcoma | Phase 1b |
Leadership Team at Monopar Therapeutics
CD
Chandler D. Robinson, MD
Chief Executive Officer, Co-Founder, and Director
AP
Andrew P. Mazar, PhD
Chief Scientific Officer, Co-Founder, and Director
CM
Christopher M. Starr, PhD
Chief Operating Officer
MJ
Michael J. Brown, JD
Chairman of the Board
AJ
Arthur J. Klausner, JD
Director
RW
Raymond W. Anderson
Director